CD262 (DR5) Monoclonal Antibody (DJR2-4 (7-8)), eBioscience™ | Invitrogen 14-9908-82 product information

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

CD262 (DR5) Monoclonal Antibody (DJR2-4 (7-8)), eBioscience™

catalog :

14-9908-82

quantity :

100 µg

price :

US 248

clonality :

monoclonal

host :

mouse

conjugate :

nonconjugated

clone name :

DJR2-4 (7-8)

reactivity :

human

application :

immunocytochemistry, flow cytometry

more info or order :

Invitrogen product webpage

citations: 32

Published Application/Species/Sample/Dilution	Reference
flow cytometry; human; fig s2	Liesche C, Venkatraman L, Aschenbrenner S, Grosse S, Grimm D, Eils R, et al. Death receptor-based enrichment of Cas9-expressing cells. BMC Biotechnol. 2016;16:17 pubmed publisher
	An Y, Jeon J, Sun L, Derakhshan A, Chen J, Carlson S, et al. Death agonist antibody against TRAILR2/DR5/TNFRSF10B enhances birinapant anti-tumor activity in HPV-positive head and neck squamous cell carcinomas. Sci Rep. 2021;11:6392 pubmed publisher
	Khawaja H, Campbell A, Roberts J, Javadi A, O Reilly P, McArt D, et al. RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer. Cell Death Dis. 2020;11:930 pubmed publisher
	Wang Y, Guo S, Li D, Tang Y, Li L, Su L, et al. YIPF2 promotes chemotherapeutic agent-mediated apoptosis via enhancing TNFRSF10B recycling to plasma membrane in non-small cell lung cancer cells. Cell Death Dis. 2020;11:242 pubmed publisher
	Carr R, Qiao G, Qin J, Jayaraman S, Prabhakar B, Maker A. Targeting the metabolic pathway of human colon cancer overcomes resistance to TRAIL-induced apoptosis. Cell Death Discov. 2016;2:16067 pubmed publisher
	Liu Y, Hawkins O, Vilgelm A, Pawlikowski J, Ecsedy J, Sosman J, et al. Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models. Clin Cancer Res. 2015;21:5338-48 pubmed publisher
	Chandrasekaran S, Marshall J, Messing J, Hsu J, King M. TRAIL-mediated apoptosis in breast cancer cells cultured as 3D spheroids. PLoS ONE. 2014;9:e111487 pubmed publisher
	Aronin A, Amsili S, Prigozhina T, Tzdaka K, Rachmilewitz J, Shani N, et al. Fn14•TRAIL effectively inhibits hepatocellular carcinoma growth. PLoS ONE. 2013;8:e77050 pubmed publisher
	Turner A, Li L, Pilli T, Qian L, Wiley E, Setty S, et al. MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells. PLoS ONE. 2013;8:e56817 pubmed publisher
	Woldemichael G, Turbyville T, Vasselli J, Linehan W, McMahon J. Lack of a functional VHL gene product sensitizes renal cell carcinoma cells to the apoptotic effects of the protein synthesis inhibitor verrucarin A. Neoplasia. 2012;14:771-7 pubmed
	Bagci Onder T, Agarwal A, Flusberg D, Wanningen S, Sorger P, Shah K. Real-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors. Oncogene. 2013;32:2818-27 pubmed publisher
	Piechocki M, Wu G, Jones R, Jacob J, Gibson H, Ethier S, et al. Induction of proapoptotic antibodies to triple-negative breast cancer by vaccination with TRAIL death receptor DR5 DNA. Int J Cancer. 2012;131:2562-72 pubmed publisher
	Kajitani K, Tanaka Y, Arihiro K, Kataoka T, Ohdan H. Mechanistic analysis of the antitumor efficacy of human natural killer cells against breast cancer cells. Breast Cancer Res Treat. 2012;134:139-55 pubmed publisher
	Li Z, Peng H, Xu Q, Ye Z. Sensitization of human osteosarcoma cells to V?9V?2 T-cell-mediated cytotoxicity by zoledronate. J Orthop Res. 2012;30:824-30 pubmed publisher
	Dompe N, Rivers C, Li L, Cordes S, Schwickart M, Punnoose E, et al. A whole-genome RNAi screen identifies an 8q22 gene cluster that inhibits death receptor-mediated apoptosis. Proc Natl Acad Sci U S A. 2011;108:E943-51 pubmed publisher
	Hanada K, Wang Q, Inozume T, Yang J. Molecular identification of an MHC-independent ligand recognized by a human {alpha}/{beta} T-cell receptor. Blood. 2011;117:4816-25 pubmed publisher
	Cabezón R, Sintes J, Llinàs L, Benitez Ribas D. Analysis of HLDA9 mAbs on plasmacytoid dendritic cells. Immunol Lett. 2011;134:167-73 pubmed publisher
	Prasmickaite L, Engesaeter B, Skrbo N, Hellenes T, Kristian A, Oliver N, et al. Aldehyde dehydrogenase (ALDH) activity does not select for cells with enhanced aggressive properties in malignant melanoma. PLoS ONE. 2010;5:e10731 pubmed publisher
	Chehimi J, Papasavvas E, Tomescu C, Gekonge B, Abdulhaqq S, Raymond A, et al. Inability of plasmacytoid dendritic cells to directly lyse HIV-infected autologous CD4+ T cells despite induction of tumor necrosis factor-related apoptosis-inducing ligand. J Virol. 2010;84:2762-73 pubmed publisher
	Sun X, Canda Sánchez A, Manjeri G, Cohen G, Pinkoski M. Phenylarsine oxide interferes with the death inducing signaling complex and inhibits tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induced apoptosis. Exp Cell Res. 2009;315:2453-62 pubmed publisher
	Ames E, Hallett W, Murphy W. Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition. Clin Exp Immunol. 2009;155:504-13 pubmed publisher
	Balsas P, López Royuela N, Galán Malo P, Anel A, Marzo I, Naval J. Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis. Biochem Pharmacol. 2009;77:804-12 pubmed publisher
	Zou W, Yue P, Khuri F, Sun S. Coupling of endoplasmic reticulum stress to CDDO-Me-induced up-regulation of death receptor 5 via a CHOP-dependent mechanism involving JNK activation. Cancer Res. 2008;68:7484-92 pubmed publisher
	Song J, Kandasamy K, Kraft A. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. J Biol Chem. 2008;283:25003-13 pubmed publisher
	Verbrugge I, de Vries E, Tait S, Wissink E, Walczak H, Verheij M, et al. Ionizing radiation modulates the TRAIL death-inducing signaling complex, allowing bypass of the mitochondrial apoptosis pathway. Oncogene. 2008;27:574-84 pubmed
	Liu X, Yue P, Chen S, Hu L, Lonial S, Khuri F, et al. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Res. 2007;67:4981-8 pubmed
	Vanoosten R, Earel J, Griffith T. Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activity. Apoptosis. 2007;12:561-71 pubmed
	Zou W, Liu X, Yue P, Khuri F, Sun S. PPARgamma ligands enhance TRAIL-induced apoptosis through DR5 upregulation and c-FLIP downregulation in human lung cancer cells. Cancer Biol Ther. 2007;6:99-106 pubmed
	Mattarollo S, Kenna T, Nieda M, Nicol A. Chemotherapy pretreatment sensitizes solid tumor-derived cell lines to V alpha 24+ NKT cell-mediated cytotoxicity. Int J Cancer. 2006;119:1630-7 pubmed
	VanOosten R, Earel J, Griffith T. Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors. Cancer Gene Ther. 2006;13:628-32 pubmed
	Ishiyama K, Ohdan H, Ohira M, Mitsuta H, Arihiro K, Asahara T. Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans. Hepatology. 2006;43:362-72 pubmed
	Earel J, Vanoosten R, Griffith T. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells. Cancer Res. 2006;66:499-507 pubmed

product information

Product Type :

Antibody

Product Name :

CD262 (DR5) Monoclonal Antibody (DJR2-4 (7-8)), eBioscience™

Catalog # :

14-9908-82

Quantity :

100 µg

Price :

US 248

Clonality :

Monoclonal

Purity :

Affinity chromatography

Host :

Mouse

Reactivity :

Human

Applications :

Flow Cytometry: 1 µg/test, Immunocytochemistry: 5 µg/mL, Immunofluorescence: 5 µg/mL

Species :

Human

Clone :

DJR2-4 (7-8)

Isotype :

IgG1, kappa

Storage :

4° C

Description :

DR5 (Apo2, TRAIL-R2, TRICK2, KILLER) is a recently identified death domain containing receptor for TRAIL, which mediates TRAIL induced apoptosis. DR5 is a member of the TNF-receptor superfamily, and contains an intracellular death domain. DR5 can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by DR5. Two transcript variants encoding different isoforms of DR5 and one non-coding transcript have been found. Overexpression of DR5 induces apoptosis and activates NF-kappa-B. DR5 is expressed in a number of cell types, and to particularly high levels in lymphocytes and spleen. Diseases associated with DR5 dysfunction include squamous cell carcinoma, and diffuse infiltrative lymphocytosis syndrome.

Format :

Liquid

Applications w/Dilutions :

Flow Cytometry: 1 µg/test, Immunocytochemistry: 5 µg/mL, Immunofluorescence: 5 µg/mL

Aliases :

apoptosis inducing protein TRICK2A/2B; apoptosis inducing receptor TRAIL-R2; CD262; cytotoxic TRAIL receptor-2; death domain containing receptor for TRAIL/Apo-2L; death receptor 5; DR5; dr-5; Fas-like protein; Killer; KILLER/DR5; KILLER/DR5 TRAIL death-inducing receptor; Ly98; MK; p53-regulated DNA damage-inducible cell death receptor(killer); sCD262; soluble CD262; TNF receptor superfamily member 10b; TNF-related apoptosis-inducing ligand receptor 2; TNFRSF10B; TRAIL receptor 2; TRAILR2; TRAIL-R2; TRICK2; TRICK2A; TRICK2B; TRICKB; tumor necrosis factor receptor superfamily member 10B; tumor necrosis factor receptor superfamily, member 10b; tumor necrosis factor receptor-like protein ZTNFR9; UNQ160/PRO186; ZTNFR9

more info or order :

Invitrogen product webpage